Willow Biosciences and Cellular Goods Announce Multiyear Supply Agreement for Cannabigerol (CBG)
June 10, 2021
Ryan Allway June 10th, 2021 VANCOUVER, BC, June 10, 2021 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQX: CANSF), a biotechnology company producing ultra-pure, sustainably made compounds, and Cellular Goods PLC (“Cellular Goods“) (LSE: CBX), a U.K. based provider of premium consumer products based on biosynthetically made cannabinoids, are... Read more
Willow Biosciences Announces Ground-Breaking Scientific Data for Cannabigerol (CBG) on Human Skin
April 20, 2021
Ryan Allway April 20th, 2021 VANCOUVER, BC, April 20, 2021 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has completed a series of studies with its development partner, Signum Biosciences, Inc., that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow’s... Read more
